Business Description
Phathom Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US71722W1071
Share Class Description:
PHAT: Ordinary sharesDescription
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
Financial Strength
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.9 | |||||
| Equity-to-Asset | -0.48 | |||||
| Debt-to-Equity | -0.94 | |||||
| Debt-to-EBITDA | -0.65 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -5.07 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 6 | |||||
| 3-Year EPS without NRI Growth Rate | -0.4 | |||||
| 3-Year FCF Growth Rate | -8.4 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 18.66 | |||||
| Future 3-5Y Total Revenue Growth Rate | 653.64 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 29.14 | |||||
| 9-Day RSI | 30.43 | |||||
| 14-Day RSI | 31.11 | |||||
| 6-1 Month Momentum % | -13.76 | |||||
| 12-1 Month Momentum % | 3.66 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.73 | |||||
| Quick Ratio | 5.68 | |||||
| Cash Ratio | 5.13 | |||||
| Days Inventory | 136.13 | |||||
| Days Sales Outstanding | 130.07 | |||||
| Days Payable | 700.92 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -26.7 | |||||
| Shareholder Yield % | -11.97 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 83.54 | |||||
| Operating Margin % | -1096.02 | |||||
| Net Margin % | -1292.14 | |||||
| FCF Margin % | -942.96 | |||||
| ROA % | -99.04 | |||||
| ROIC % | -757.71 | |||||
| ROC (Joel Greenblatt) % | -8608.73 | |||||
| ROCE % | -91.29 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 17.73 | |||||
| EV-to-EBIT | -1.29 | |||||
| EV-to-EBITDA | -1.29 | |||||
| EV-to-Revenue | 13.37 | |||||
| EV-to-Forward-Revenue | 2.64 | |||||
| EV-to-FCF | -1.46 | |||||
| Earnings Yield (Greenblatt) % | -77.52 | |||||
| FCF Yield % | -47.61 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:PHAT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Phathom Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 26.27 | ||
| EPS (TTM) ($) | -5.75 | ||
| Beta | 0.2 | ||
| Volatility % | 101.01 | ||
| 14-Day RSI | 31.11 | ||
| 14-Day ATR ($) | 0.750727 | ||
| 20-Day SMA ($) | 8.409 | ||
| 12-1 Month Momentum % | 3.66 | ||
| 52-Week Range ($) | 6.065 - 19.71 | ||
| Shares Outstanding (Mil) | 68.38 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Phathom Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Phathom Pharmaceuticals Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Phathom Pharmaceuticals Inc Frequently Asked Questions
What is Phathom Pharmaceuticals Inc(PHAT)'s stock price today?
The current price of PHAT is $7.50. The 52 week high of PHAT is $19.71 and 52 week low is $6.07.
When is next earnings date of Phathom Pharmaceuticals Inc(PHAT)?
The next earnings date of Phathom Pharmaceuticals Inc(PHAT) is 2025-03-07 Est..
Does Phathom Pharmaceuticals Inc(PHAT) pay dividends? If so, how much?
Phathom Pharmaceuticals Inc(PHAT) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers